Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let’s see if TLRY stock is a good buy right now.

| More on:
a person watches a downward arrow crash through the floor

Source: Getty Images

Similar to most other Canadian cannabis stocks, Tilray (TSX:TLRY) underperformed the broader markets by a wide margin in 2022. Shares of the Canadian marijuana giant fell close to 60% in the last 12 months and are currently trading 92% below all-time highs. Let’s see why.

Industry-wide issues

Canadian marijuana producers have been wrestling with a variety of industry-wide issues ever since pot was legalized in the country in October 2018. Tilray and its peers were initially impacted by the slow rollout of retail stores in major provinces as well as competition from a thriving black market.

Soon after marijuana was legalized in Canada, several producers went on a shopping spree and acquired competitors at a hefty premium to increase market share and enter other verticals. They also increased production capacity at an accelerated pace to benefit from economies of scale.

However, a thriving black market and lower-than-expected demand resulted in lukewarm sales and tepid revenue growth in the last four years. Further, overvalued acquisitions led to multi-billion-dollar write-downs, while rising competition and oversupply of cannabis resulted in negative profit margins.

To offset high cash-burn rates, almost every cannabis company on the TSX raised equity or debt capital several times, leading to a weak balance sheet and shareholder dilution.

Cannabis remains illegal south of the border

Shortly after the presidential election in the U.S. in late 2020, cannabis stocks gained pace in the following months. Investors expected the U.S. Democratic Party to legalize or at least decriminalize marijuana at the federal level.

Further, it was also anticipated that the SAFE Banking Act would pass in the U.S. Congress, providing traditional access to capital to marijuana businesses in the country.

But these expectations did not materialize, which accelerated the selloff among pot stocks in 2022. The Canadian cannabis market is quite small compared to the U.S. market. If recreational marijuana were legalized in the U.S., Canadian licensed producers would be well poised to benefit by gaining access to a rapidly expanding multi-billion-dollar market.

The legalization of pot in the U.S. will be a key tailwind for Tilray and its peers in the upcoming decade.

What’s next for Tilray stock and investors?

Tilray is currently valued at a market cap of US$1.68 billion and reported sales of US$628.37 million in fiscal 2022 (ended in May). Valued at less than three times trailing sales, Tilray expects sales to surpass US$4 billion annually by fiscal 2024, which is quite an ambitious goal.

For Tilray to achieve its revenue-growth forecasts, it will have to acquire companies aggressively or depend on legalization in the United States and Europe. It ended the August quarter with less than US$500 million in cash, suggesting Tilray will have to infuse additional capital to pursue inorganic growth.

Alternatively, Tilray is positioned to cash in if the U.S. and other markets legalize pot for recreational use. In 2021, Tilray disclosed a strategic transaction with MedMen, a multi-state operator in the United States. Tilray acquired US$165.8 million of convertible debt in MedMen, which will convert into ownership in the event of marijuana legalization.

Tilray also acquired multiple distilleries and beer breweries to enhance its distribution network and enter the edibles segment.

Similarly, Tilray has a sizeable presence in Germany, which is on track to legalize adult-use cannabis in the next two years.

The Foolish takeaway

Tilray remains a high-risk bet due to industry-wide challenges impacting the company as well as uncertainties surrounding pot legalization in international markets. Analysts remain bullish on the stock and expect it to surge over 80% in the next 12 months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Forget Canopy Growth: 1 Cannabis Stock With Far Less Risk

Cannabis stocks like Canopy Growth (TSX:WEED) haven't done well for quite some time, yet this one deserves a major boost!

Read more »